Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 7Active not recruiting 2Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 8Gastrointestinal 5Thoracic 3Breast 3Other hematologic neoplasm 2Head & Neck 2CNS 2Tumor-Agnostic 1Plasma cell 1Gynecologic 1Dermatologic 1

Conditions

Neuroblastoma 1Hemangioma, Cavernous, Central Nervous System 1Hemangioma, Cavernous 1Ganglioneuroblastoma 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Watchful Waiting × CNS × Clear all
NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

Phase 3 Active not recruiting
621 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT04467489 2025-08-11

Biomarkers of CASH

University of Chicago

Active not recruiting
1,040 enrolled
CNS

Hemangioma, Cavernous, Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡